Medications

Upadacitinib beats placebo for psoriatic arthritis

For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine.

Diseases, Conditions, Syndromes

Minority patients with rheumatic diseases have worse COVID-19 outcomes

New research at ACR Convergence, the American College of Rheumatology's annual meeting, reveals that people of color with rheumatic disease have worse health outcomes from COVID-19 infection, are more likely to be hospitalized ...

page 6 from 11